Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer

Background: Inflammation represents a pivotal role in the progression of cervical cancer. The hematological markers of inflammation in complete blood count (CBC) panel are potentially useful in determining the prognosis of the disease. Objective: The aim of the study was to investigate whether the p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asian Pacific Journal of Cancer Prevention 2019-03, Vol.20 (3), p.863-868
Hauptverfasser: Prabawa, I Putu Yuda, Bhargah, Agha, Liwang, Firdy, Tandio, Deasy Ayuningtyas, Tandio, Aditya Leonard, Lestari, Anak Agung Wiradewi, Budiana, I Nyoman Gede, Manuaba, Ida Bagus Amertha Putra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 868
container_issue 3
container_start_page 863
container_title Asian Pacific Journal of Cancer Prevention
container_volume 20
creator Prabawa, I Putu Yuda
Bhargah, Agha
Liwang, Firdy
Tandio, Deasy Ayuningtyas
Tandio, Aditya Leonard
Lestari, Anak Agung Wiradewi
Budiana, I Nyoman Gede
Manuaba, Ida Bagus Amertha Putra
description Background: Inflammation represents a pivotal role in the progression of cervical cancer. The hematological markers of inflammation in complete blood count (CBC) panel are potentially useful in determining the prognosis of the disease. Objective: The aim of the study was to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be used as in predicting the stage of cervical cancer. Methods: A retrospective cross-sectional study involving 282 patients with cervical cancer was enrolled at Sanglah General Hospital for five years (2013-2017). The histopathological records and complete blood counts (CBC) of the patients were collected and analyzed using SPSS ver. 16 software. FIGO stage I–II and III-IV were classified as early and advance stage respectively. Results: The median NLR and PLR were significantly higher in the advance stage compared with early stage (7.58 (1.36-33.20) and 247.89 (97.10-707.11); p-value = 0.001). A strong positive correlation was found between the staging of cervical cancer and NLR (r=0.638) and PLR (r=0.668). The AUC, sensitivity, and specificity value of NLR and PLR were 0.803 (82%; 71%) and 0.716 (72%; 70%). Advanced stage of cervical cancer was found in high NLR (adjusted OR: 9.02; 95%CI=2.42-33.64; p=0.001) and PLR (adjusted OR = 2.47; 95% CI = 1.45-4.85; p = 0.032). Conclusion: Increased pretreatment NLR and PLR values may provide a useful information in predicting the staging of cervical cancer.
doi_str_mv 10.31557/apjcp.2019.20.3.863
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825764</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30912405</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4403-9c2a986a2bb1c08f2b5eb8376595bf0917c2e3e8dfdd6b365a1362b6b64d8daf3</originalsourceid><addsrcrecordid>eNpdUU1v1DAQtRCoX_QfIOQjHLI4duwkl0pVRFvQtkQVIG7W2Jl03SZx5HhX2r_SX0vYharlMjOaee-NZh4h71K2EKmU-ScY7-244Cwt57AQi0KJV-SIZ7lKcsV_vX5WH5LjabpnLJNFLg_IoWBlyjMmj8hjHTAGhNjjEOkNrmPw48p1SfTJctuPK2-3EWmA6Dz9cLO8_UhhaGjdQcQO43-w2z2s3sEmCnRWb5yNboP0J3RrpL6lV9hD9J2_cxY6eg3hAcNE3UArDJtdr4LBYnhL3rTQTXj6N5-QHxefv1dXyfLb5ZfqfJnYLGMiKS2HslDAjUktK1puJJpC5EqW0rTzobnlKLBo2qZRRigJqVDcKKOypmigFSfkbK87rk2PjZ0fEaDTY3A9hK324PTLyeBW-s5vtCq4zFU2C2R7ARv8NAVsn7gp0zuv9Hn9tar1H6_moIWevZpp75_vfSL9M0f8BqZklMA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Prabawa, I Putu Yuda ; Bhargah, Agha ; Liwang, Firdy ; Tandio, Deasy Ayuningtyas ; Tandio, Aditya Leonard ; Lestari, Anak Agung Wiradewi ; Budiana, I Nyoman Gede ; Manuaba, Ida Bagus Amertha Putra</creator><creatorcontrib>Prabawa, I Putu Yuda ; Bhargah, Agha ; Liwang, Firdy ; Tandio, Deasy Ayuningtyas ; Tandio, Aditya Leonard ; Lestari, Anak Agung Wiradewi ; Budiana, I Nyoman Gede ; Manuaba, Ida Bagus Amertha Putra</creatorcontrib><description>Background: Inflammation represents a pivotal role in the progression of cervical cancer. The hematological markers of inflammation in complete blood count (CBC) panel are potentially useful in determining the prognosis of the disease. Objective: The aim of the study was to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be used as in predicting the stage of cervical cancer. Methods: A retrospective cross-sectional study involving 282 patients with cervical cancer was enrolled at Sanglah General Hospital for five years (2013-2017). The histopathological records and complete blood counts (CBC) of the patients were collected and analyzed using SPSS ver. 16 software. FIGO stage I–II and III-IV were classified as early and advance stage respectively. Results: The median NLR and PLR were significantly higher in the advance stage compared with early stage (7.58 (1.36-33.20) and 247.89 (97.10-707.11); p-value = 0.001). A strong positive correlation was found between the staging of cervical cancer and NLR (r=0.638) and PLR (r=0.668). The AUC, sensitivity, and specificity value of NLR and PLR were 0.803 (82%; 71%) and 0.716 (72%; 70%). Advanced stage of cervical cancer was found in high NLR (adjusted OR: 9.02; 95%CI=2.42-33.64; p=0.001) and PLR (adjusted OR = 2.47; 95% CI = 1.45-4.85; p = 0.032). Conclusion: Increased pretreatment NLR and PLR values may provide a useful information in predicting the staging of cervical cancer.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/apjcp.2019.20.3.863</identifier><identifier>PMID: 30912405</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Adenocarcinoma - pathology ; Blood Platelets - pathology ; Carcinoma, Squamous Cell - pathology ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Humans ; Lymphocytes - pathology ; Middle Aged ; Neutrophils - pathology ; Prognosis ; Retrospective Studies ; ROC Curve ; Uterine Cervical Neoplasms - pathology</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2019-03, Vol.20 (3), p.863-868</ispartof><rights>Creative Commons Attribution License</rights><rights>Copyright: © Asian Pacific Journal of Cancer Prevention 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4403-9c2a986a2bb1c08f2b5eb8376595bf0917c2e3e8dfdd6b365a1362b6b64d8daf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825764/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825764/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30912405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prabawa, I Putu Yuda</creatorcontrib><creatorcontrib>Bhargah, Agha</creatorcontrib><creatorcontrib>Liwang, Firdy</creatorcontrib><creatorcontrib>Tandio, Deasy Ayuningtyas</creatorcontrib><creatorcontrib>Tandio, Aditya Leonard</creatorcontrib><creatorcontrib>Lestari, Anak Agung Wiradewi</creatorcontrib><creatorcontrib>Budiana, I Nyoman Gede</creatorcontrib><creatorcontrib>Manuaba, Ida Bagus Amertha Putra</creatorcontrib><title>Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>Background: Inflammation represents a pivotal role in the progression of cervical cancer. The hematological markers of inflammation in complete blood count (CBC) panel are potentially useful in determining the prognosis of the disease. Objective: The aim of the study was to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be used as in predicting the stage of cervical cancer. Methods: A retrospective cross-sectional study involving 282 patients with cervical cancer was enrolled at Sanglah General Hospital for five years (2013-2017). The histopathological records and complete blood counts (CBC) of the patients were collected and analyzed using SPSS ver. 16 software. FIGO stage I–II and III-IV were classified as early and advance stage respectively. Results: The median NLR and PLR were significantly higher in the advance stage compared with early stage (7.58 (1.36-33.20) and 247.89 (97.10-707.11); p-value = 0.001). A strong positive correlation was found between the staging of cervical cancer and NLR (r=0.638) and PLR (r=0.668). The AUC, sensitivity, and specificity value of NLR and PLR were 0.803 (82%; 71%) and 0.716 (72%; 70%). Advanced stage of cervical cancer was found in high NLR (adjusted OR: 9.02; 95%CI=2.42-33.64; p=0.001) and PLR (adjusted OR = 2.47; 95% CI = 1.45-4.85; p = 0.032). Conclusion: Increased pretreatment NLR and PLR values may provide a useful information in predicting the staging of cervical cancer.</description><subject>Adenocarcinoma - pathology</subject><subject>Blood Platelets - pathology</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lymphocytes - pathology</subject><subject>Middle Aged</subject><subject>Neutrophils - pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Uterine Cervical Neoplasms - pathology</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1v1DAQtRCoX_QfIOQjHLI4duwkl0pVRFvQtkQVIG7W2Jl03SZx5HhX2r_SX0vYharlMjOaee-NZh4h71K2EKmU-ScY7-244Cwt57AQi0KJV-SIZ7lKcsV_vX5WH5LjabpnLJNFLg_IoWBlyjMmj8hjHTAGhNjjEOkNrmPw48p1SfTJctuPK2-3EWmA6Dz9cLO8_UhhaGjdQcQO43-w2z2s3sEmCnRWb5yNboP0J3RrpL6lV9hD9J2_cxY6eg3hAcNE3UArDJtdr4LBYnhL3rTQTXj6N5-QHxefv1dXyfLb5ZfqfJnYLGMiKS2HslDAjUktK1puJJpC5EqW0rTzobnlKLBo2qZRRigJqVDcKKOypmigFSfkbK87rk2PjZ0fEaDTY3A9hK324PTLyeBW-s5vtCq4zFU2C2R7ARv8NAVsn7gp0zuv9Hn9tar1H6_moIWevZpp75_vfSL9M0f8BqZklMA</recordid><startdate>20190326</startdate><enddate>20190326</enddate><creator>Prabawa, I Putu Yuda</creator><creator>Bhargah, Agha</creator><creator>Liwang, Firdy</creator><creator>Tandio, Deasy Ayuningtyas</creator><creator>Tandio, Aditya Leonard</creator><creator>Lestari, Anak Agung Wiradewi</creator><creator>Budiana, I Nyoman Gede</creator><creator>Manuaba, Ida Bagus Amertha Putra</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190326</creationdate><title>Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer</title><author>Prabawa, I Putu Yuda ; Bhargah, Agha ; Liwang, Firdy ; Tandio, Deasy Ayuningtyas ; Tandio, Aditya Leonard ; Lestari, Anak Agung Wiradewi ; Budiana, I Nyoman Gede ; Manuaba, Ida Bagus Amertha Putra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4403-9c2a986a2bb1c08f2b5eb8376595bf0917c2e3e8dfdd6b365a1362b6b64d8daf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Blood Platelets - pathology</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lymphocytes - pathology</topic><topic>Middle Aged</topic><topic>Neutrophils - pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Uterine Cervical Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prabawa, I Putu Yuda</creatorcontrib><creatorcontrib>Bhargah, Agha</creatorcontrib><creatorcontrib>Liwang, Firdy</creatorcontrib><creatorcontrib>Tandio, Deasy Ayuningtyas</creatorcontrib><creatorcontrib>Tandio, Aditya Leonard</creatorcontrib><creatorcontrib>Lestari, Anak Agung Wiradewi</creatorcontrib><creatorcontrib>Budiana, I Nyoman Gede</creatorcontrib><creatorcontrib>Manuaba, Ida Bagus Amertha Putra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prabawa, I Putu Yuda</au><au>Bhargah, Agha</au><au>Liwang, Firdy</au><au>Tandio, Deasy Ayuningtyas</au><au>Tandio, Aditya Leonard</au><au>Lestari, Anak Agung Wiradewi</au><au>Budiana, I Nyoman Gede</au><au>Manuaba, Ida Bagus Amertha Putra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2019-03-26</date><risdate>2019</risdate><volume>20</volume><issue>3</issue><spage>863</spage><epage>868</epage><pages>863-868</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Background: Inflammation represents a pivotal role in the progression of cervical cancer. The hematological markers of inflammation in complete blood count (CBC) panel are potentially useful in determining the prognosis of the disease. Objective: The aim of the study was to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be used as in predicting the stage of cervical cancer. Methods: A retrospective cross-sectional study involving 282 patients with cervical cancer was enrolled at Sanglah General Hospital for five years (2013-2017). The histopathological records and complete blood counts (CBC) of the patients were collected and analyzed using SPSS ver. 16 software. FIGO stage I–II and III-IV were classified as early and advance stage respectively. Results: The median NLR and PLR were significantly higher in the advance stage compared with early stage (7.58 (1.36-33.20) and 247.89 (97.10-707.11); p-value = 0.001). A strong positive correlation was found between the staging of cervical cancer and NLR (r=0.638) and PLR (r=0.668). The AUC, sensitivity, and specificity value of NLR and PLR were 0.803 (82%; 71%) and 0.716 (72%; 70%). Advanced stage of cervical cancer was found in high NLR (adjusted OR: 9.02; 95%CI=2.42-33.64; p=0.001) and PLR (adjusted OR = 2.47; 95% CI = 1.45-4.85; p = 0.032). Conclusion: Increased pretreatment NLR and PLR values may provide a useful information in predicting the staging of cervical cancer.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>30912405</pmid><doi>10.31557/apjcp.2019.20.3.863</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2476-762X
ispartof Asian Pacific Journal of Cancer Prevention, 2019-03, Vol.20 (3), p.863-868
issn 2476-762X
1513-7368
2476-762X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825764
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals
subjects Adenocarcinoma - pathology
Blood Platelets - pathology
Carcinoma, Squamous Cell - pathology
Cross-Sectional Studies
Female
Follow-Up Studies
Humans
Lymphocytes - pathology
Middle Aged
Neutrophils - pathology
Prognosis
Retrospective Studies
ROC Curve
Uterine Cervical Neoplasms - pathology
title Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T17%3A22%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20Neutrophil-to-Lymphocyte%20ratio%20(NLR)%20and%20Platelet-to-Lymphocyte%20Ratio%20(PLR)%20as%20a%20Predictive%20Value%20of%20Hematological%20Markers%20in%20Cervical%20Cancer&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=Prabawa,%20I%20Putu%20Yuda&rft.date=2019-03-26&rft.volume=20&rft.issue=3&rft.spage=863&rft.epage=868&rft.pages=863-868&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/apjcp.2019.20.3.863&rft_dat=%3Cpubmed_cross%3E30912405%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30912405&rfr_iscdi=true